Pulse Biosciences, Inc. will report its business updates and financial results for the second quarter of 2026 after the market closes on Thursday, August 6, 2026. The company, which leverages its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, scheduled the release to provide investors with an update on its operational progress.

Conference Call Details

Company management will host a conference call to discuss these business updates and financial results. The call is scheduled to begin at 1:30pm PT / 4:30pm ET on the same day.

Investors can access the live call by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally. Participants must provide Conference ID 3486060 to join.

Webcast Access

A live and recorded webcast of the conference call will be available on the Pulse Biosciences Investors website. This allows stakeholders to listen to the discussion via the internet.

Company Overview

Pulse Biosciences focuses on bioelectric medicine, utilizing its nPulse technology to deliver nanosecond pulses of electrical energy. This non-thermal approach aims to clear cells while sparing adjacent tissue. The company is developing this technology for treating atrial fibrillation and other specific markets.

Pulse Biosciences has granted inducement options to purchase an aggregate of 9,000 shares of common stock to three new employees. The awards were approved and issued on July 13, 2026, by the independent Compensation Committee of its Board of Directors. The grants were made under the 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options carry an exercise price of $25.89 per share, which equals the closing price of the company's common stock on July 13, 2026. Vesting occurs over four years, with 25% of each award vesting annually, subject to the employee's continued employment with Pulse Biosciences. The options are subject to the terms and conditions of the 2017 Inducement Equity Incentive Plan and the award agreements.

Inducement Award Details

Pulse Biosciences is a bioelectric medicine company leveraging its proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology. The company focuses on developing its nPulse technology for the treatment of atrial fibrillation and other markets.